MGRX · Company research
Mangoceuticals, Inc. Common Stock (MGRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| MGRX Q3 2025 Earnings: Quarterly Loss of $0.69 per Share Met With a 9.24% Stock Decline - Margin Compression Risk - https://www.siam.in/ | MGRX Q3 2025 Earnings: Quarterly Loss of $0.69 per Share Met With a 9.24% Stock Decline - Margin Compression Risk https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 12, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals, Inc. (MGRX) Stock Price & News - Syfe | Mangoceuticals, Inc. (MGRX) Stock Price & News Syfe | View source ↗ | Syfe | Oct 12, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals (MGRX) Shares Rise 7.66% to $0.45 as Buyers Test Near-Term Resistance - Low Vol Factor - https://www.dars.gov.et/ | Mangoceuticals (MGRX) Shares Rise 7.66% to $0.45 as Buyers Test Near-Term Resistance - Low Vol Factor https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 7, 2026 | neutral | 0 | 0.6 |
| CFO receives 100,000 shares at Mangoceuticals (MGRX), holds 220,000 directly afterward. - Stock Titan | CFO receives 100,000 shares at Mangoceuticals (MGRX), holds 220,000 directly afterward. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| With 1.63M option shares included, Mangoceuticals (MGRX) CEO reports his ownership stake. - Stock Titan | With 1.63M option shares included, Mangoceuticals (MGRX) CEO reports his ownership stake. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| For board services, Mangoceuticals (MGRX) director Alex P. Hamilton received 100,000 shares. - Stock Titan | For board services, Mangoceuticals (MGRX) director Alex P. Hamilton received 100,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why - Benzinga | Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why Benzinga | View source ↗ | Benzinga | Oct 2, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche | Mangoceuticals announced that its subsidiary MangoRx IP Holdings has secured $2.5 million in strategic investment from two investors for a 25% membership interest. The initial $1.75 million tranche has been received, with the remaining $750,000 due by November 28, 2026. The investment will fund commercialization of the company's antiviral intellectual property portfolio covering oral-surface administered preparations, with potential applications in poultry, livestock, and human oral-care markets valued at approximately $74.6 billion combined. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche | Mangoceuticals announced that its subsidiary MangoRx IP Holdings has secured $2.5 million in strategic investment from two investors for a 25% membership interest. The initial $1.75 million tranche has been received, with the remaining $750,000 due by November 28, 2026. The investment will fund commercialization of the company's antiviral intellectual property portfolio covering oral-surface administered preparations, with potential applications in poultry, livestock, and human oral-care markets valued at approximately $74.6 billion combined. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Investors agreed to buy 25% of Mangoceuticals’ company holding antiviral patents for $2.5 million. - Stock Titan | Investors agreed to buy 25% of Mangoceuticals’ company holding antiviral patents for $2.5 million. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| MANGOCEUTICALS, INC. Q2 2026: Revenue $68.76K, EPS $(0.09) — 10-Q Summary - TradingView | MANGOCEUTICALS, INC. Q2 2026: Revenue $68.76K, EPS $(0.09) — 10-Q Summary TradingView | View source ↗ | TradingView | Aug 13, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why - Benzinga | Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why Benzinga | View source ↗ | Benzinga | Aug 6, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals Granted 180-Day Extension by Nasdaq to - GlobeNewswire | Mangoceuticals Granted 180-Day Extension by Nasdaq to GlobeNewswire | View source ↗ | GlobeNewswire | Aug 4, 2026 | neutral | 0 | 0.6 |
| Market Movers | Winners: FWAC, REPL, MGRX | Losers: KPTI, BIOA, MBRX - Trefis | Market Movers | Winners: FWAC, REPL, MGRX | Losers: KPTI, BIOA, MBRX Trefis | View source ↗ | Trefis | Aug 3, 2026 | neutral | 0 | 0.6 |
| MGRX surges after Nuclea Energy reverse-merger deal reshapes company story - Quiver Quantitative | MGRX surges after Nuclea Energy reverse-merger deal reshapes company story Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 31, 2026 | neutral | 0 | 0.6 |
| Market Movers | Winners: CYCU, GCTK, KSCP | Losers: MGRX, CCB, YYAI - Trefis | Market Movers | Winners: CYCU, GCTK, KSCP | Losers: MGRX, CCB, YYAI Trefis | View source ↗ | Trefis | Jul 31, 2026 | neutral | 0 | 0.6 |
| Mangoceuticals to Combine With Nuclea Energy; Nuclea Holders to Own ~96% Pre-PIPE - TradingView | Mangoceuticals to Combine With Nuclea Energy; Nuclea Holders to Own ~96% Pre-PIPE TradingView | View source ↗ | TradingView | Jul 30, 2026 | neutral | 0 | 0.6 |
| Thursday's after hours session: top gainers and losers - ChartMill | Thursday's after hours session: top gainers and losers ChartMill | View source ↗ | ChartMill | Jul 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.